"So why the fervor for Allergan? In Sanofi's case, sources told Pharmawire, it's Allergan's products for eye and ear problems, plus cosmetic drugs, including those for hair loss. (The sources said a smaller deal for similar meds might be easier to pull off, though.) But Pharmawire also speculates that it's CEO Chris Viehbacher who's enamored with Allergan. Last year, Allergan turned down an informal deal proposal from GSK--and Viehbacher was Glaxo's president for North American pharmaceuticals at the time. Now that he's at Sanofi, he's still eyeing Allergan's considerable assets. Or so the talk goes."